2023 Seventh International Conference on Image Information Processing (ICIIP) | 979-8-3503-7140-6/23/$31.00 ©2023 IEEE | DOI: 10.1109/ICIIP61524.2023.10537645

# DeepPharma: Revolutionizing Drug Discovery through Kernelled Drug Prediction Based on Similarity Matrix

[1]Medepalli David Raju,
*Associate Professor and Dy HOD,Department of Chemistry, P.B.Siddhartha College of Arts&Science, Vijayawada, Andhra Pradesh, India*
mdavidraju40@gmail.com

[2]Santosh Karajgi,
*Professor and Head,Department of Pharmaceutical Quality Assurance,BLDEA's SSM College of Pharmacy and Research Centre Vijayapur 586103,Vijayapura, Karnataka,India,*
*santosh.karajgi@gmail.com*

[3]Mayank,
*Assistant professor, Biochemical engineering department, B.T. Kumaon Institute of Technology Dwarahat, Almora-263653,Uttarakhand,India,*
*findmayank12@yahoo.co.in*

[4]Pramod Singh Kunwar,
*Department of Pharmaceutics, School of Pharmacy, Mount Kenya University, Kenya,*
*pkunwar@mku.ac.ke*

[5]Jyoti Dhanke,
*Assistant Professor, Department of Engineering Science (Mathematics), Bharati Vidyapeeth's College of Engineering, Lavale, Pune 412115, Maharashtra, India,*
*jyoti.dhanke@bharatividyapeeth.edu*

[6]R. N. Patil,
*Principal, Department of Mechanical Engineering, Bharati Vidyapeeth's College of Engineering Lavale Pune, India,*
*rajendrakumar.patil@bharatividyapeeth.ed*

*Abstract*-**Cancer poses a formidable and diverse challenge, as patients with the same type of cancer exhibit varying responses to targeted therapy. The need to develop new drugs and tailor treatment plans for individual patients becomes imperative. However, the high costs and extended duration of clinical trials present significant barriers to the advancement of cancer treatments. To overcome these hurdles, there is an urgent demand for a predictive methodology that can anticipate medication responses and facilitate personalized treatment strategies. To address this requirement, we propose an innovative approach called "Kernelled Drug Prediction Based on Similarity Matrix." This study focuses on utilizing this method to accurately predict drug responses and customize therapies for specific individuals. To assess the robustness of our proposed method, we employ a 10-fold cross-validation technique. In this process, the dataset is divided into ten equal parts, with one part used for testing and the remaining nine parts for training during each iteration. For validation, we utilize the Cancer Cell Line Encyclopedia (CCLE) dataset, which includes activity area as drug response parameters, with a dimensionality (k) set as 10 for the CCLE dataset. Our study aims to offer a practical and efficient solution to predict drug responses and pave the way for personalized cancer treatment strategies. Through this research, we contribute to the advancement of cancer treatment by providing a more streamlined and accurate means of predicting drug responses, potentially leading to improved patient outcomes and optimized therapeutic interventions.**

***Keywords— : Cancer, Heterogeneity, Targeted therapies, Personalized treatment, New drugs and Clinical trials***

## I. INTRODUCTION

The availability of vast multiomics data has played a crucial role in making precision medicine or personalized medicine a practical and widely adopted approach in cancer treatment. This data provides comprehensive characterization of individual cancer samples, enabling a more targeted and tailored approach to treatment. A prominent example of such a resource is the Cancer Genome Atlas (TCGA) program, which offers multiomics data, including gene expression, copy number variation (CNV), genetic mutation, methylation, proteomics, and clinical outcome information for over 20,000 cancer patients across 33 different cancer types and subtypes (Goldman et al., 2018). Cancer cell lines also serve as valuable experimental models for identifying significant biomarkers and conducting drug screenings in the laboratory. The Broad University Cancer Cellular Line Encyclopedia (CCLE) covers more than 1,000 cancer cell lines, providing multiomics data to researchers (Barretina et al., 2012; Wang et al., 2019). Additionally, the Genetics of Drug Sensitivity in Cancer (GDSC) dataset includes information on the drug sensitivity of 1,000 cancer cell lines to 100 different drugs and chemicals, aiming to discover associations between genetic markers and therapeutic effects (Garnett et al., 2012; Yang et al., 2013).

These extensive databases are instrumental in enhancing our understanding of how genetic information and pharmaceutical susceptibility intersect in cancer research. The NCI-ALMANAC drug Combination library, as highlighted by Holbeck et al. (2017), contributes to this effort with 5,232 screens of medication combinations tested against 60 diverse types of cancer cells. By leveraging these vast databases, researchers can gain insights into the fundamental biological mechanisms underlying the diversity and complexity of cancers, as well as identify potential drivers of reactions (MoR) to chemotherapy and radiation treatments.

However, integrating and meaningfully interpreting the many and varied points of information in high-dimensional multiomics information continues to be difficult. Decoding and comprehending the sophisticated signaling systems that control the response to anticancer treatments utilizing high-dimensional multiomics databases is still a challenging endeavor despite the identification of links among particular biomarkers and medication response. An adaptive net approach was applied to find relationships among metabolites or reaction to drugs in CCLE and GDSC information (Barretina et al., 2012; Garnett et al., 2012; Yang

et al., 2013; Wang et al., 2019). Using compounds from chemicals and multiomics-based similarity across cancer cell lines, Wang et al. (2016) suggested an SVM-based model for predicting responses to medications. Models of networks based on drug-cancer cell line similarities and system recommendations (Suphavilai et al., 2018) have also been presented to predict the effect of drugs. These strategies make use of various computer science and network-based strategies in an attempt to enhance medication reaction predictions and comprehension.

## II. Related Survey

Several deep learning models have been put out to forecast medication reaction. In order to minimize the dimension of characteristics acquired from chemical structure and omics data, Li et al. (2019) utilized an auto-encoder. They then used a DNNs to predict the reaction to the drug. Sakellaropoulos et al. (2019) built a DNN paradigm that used gene expression data to predict anticancer treatment response, outperforming machine learning frameworks. Similar neural network models have also been suggested for predicting how drug mixtures will react to chemotherapy drugs. Chemical structure and genetic properties of cancer cell lines and patients were included into autonomous encoders utilizing Deep Synergi (Preuer et al., 2018) and AuDNN synergy (Zhang et al., 2018). DCell and Drug Cell are two examples of visible neural networks (VNN) architectures that have been presented (Yu et al., 2018; Kong et al., 2020; Kuenzi et al., 2020). These mathematical models used huge hierarchical frameworks for deep learning to describe the hierarchy structure of biological functions and anticipate how medications will work using key variables. Drug Cell examined pathway-level activity using omics data and biochemical structural information. Furthermore, Path-DNN (Deng et al., 2020) and PASNet (Hao et al., 2018) both offered approaches that used biological network data in the prediction models.

PASNet predicts cancer prognoses using gene expression data. Path-DNN (Deng et al., 2020) used gene expression data from a set of marker transcripts and generic pathways from KEGG to forecast responses to drugs. ConsDeep Signaling assessed the activity of 46 pathways for signaling from the KEGG signalling route database structure, encompassing the 45 identified routes and the cellular cycle path (Feng et al., 2020; Ogata et al., 1999; Kanehisa and go to, 2000; Zhang et al., 2020). Data on expression of genes and variation in copies were included in this investigation. It aims to ease the research of biological signaling pathways by understanding the models from a broad standpoint. In cancer research, signaling pathways reflect cascades of signaling events among a collection of genes/proteins, providing biological relevance and understanding for response to treatment (Sanchez-Vega et al., 2018). To examine how a deep learning model bound by the 46 signals may be used to predict the anticancer treatment response. Omics data from CCLE lines of cancer cells and medication response information from GDSC were used for testing and contrasting the suggested framework to current algorithms.

## III. Proposed Model

The structure for similarity-based drug prediction of target that has been previously laid out [73] serves as the basis for the suggested strategy. It is predicated on the concept that medicines and cell lines with comparable properties often display comparable drug responses. Prediction is based on tissue (cell-line) and medication similarity. Predicting reactions to medications that do not yet exist or are absent is the goal of drug response prediction. The input data is split into a training set (IT) as in (1) and a test set (Ix) based on a proportion x, such that IT Ix = I and IT Ix =, in order to verify the approach. There are three primary steps in the suggested technique. Second, similarity ratings between drugs and tissues are calculated as in (2). Finally, a regularized matrix factorization technique is used to recreate the initial reaction matrices using the drug-drug and tissue-tissue resemblance data. The suggested response to drug prediction model's operation is shown in Fig.1 Latent vectors that represent medicine and cell lines are used to tackle the approximation issue, and an objective function is minimized as a result.




Fig.1 Working model of the proposed strategy

$$\min X,Y \; \|R - XY^T\|^2_F \quad (1)$$

Regularisation [24,25] limits are placed on the extent of X and Y to prevent over fitting. A complying with objective purpose is then utilised.

.

$$\min X,Y \; \|R - XY^T\|^2_F + \beta\|X|^2_F + Y|^2_F \quad (2)$$

WhereR_ijs the identified response to drug for drug di and cell-line ci that produces $XY^T \approx R$. X_iand y_iare the underlying variables representing the characteristics of medicinal products and cell-lines, as well.

### A. Drug-Drug Similar Matrices

When there are structural similarities between fd_i and fd_j, they are considered to be structurally similar. If D represents the set of known substances that includes both di and dj, then D can be expressed as D = {d_i,d_j} as in (3). The DNA fingerprints fd_iand fdj must be obtained by executing the R programme (rcdk) using SMILES information, then the score for similarity S (d_i,d_j) may be determined by utilising the Tanimoto factor.

$$S(d_i, d_j) = r/(p+q+r) \quad (3)$$

Where, r is the common fingerprint between fd_iand fd_j .

### B. Tissue2Tissue Similar Matrices

Therefore, relying solely on the genes targeted by a medication to determine cell-line similarity is not the optimal approach. It is necessary to also consider genes associated with drug resistance, as they can significantly influence the overall response to medication. When calculating cell-line similarity as in (4), the effects of the top k comparable medications that align with a specific cell-line are taken into consideration. Furthermore, the fold change for a particular gene g_i is computed as,

$$F(g\_i)=(avg(xij|yjk>0,j=1toN))/(avg(xij|yjk<0,j=1toN)) \quad (4)$$

The equation uses N to represent the total count of cell lines, and xij to represent the level of gene g_i expression. To identify important gene signatures for a specific medicine, the top 1% of genes with the largest changes in expression values are selected. This process is applied to calculate gene signatures for each of the k drugs. Finally, the TABLE I issue similarity score S(c_i,c_j) between two cell lines, c_iand c_j, in the set C, is determined using the Pearson correlation coefficient.

TABLE I. SYMBOLS USED IN THE PROPOSED STRATEGY

| Symbol | Meaning |
|---|---|
| R | Drug Response Matrix |
| K | Dimensionality of latent features |
| C | Cell-line similarity matrices |
| β | Regularization parameter for drug |
| λ | Learning rate |
| D | Drug similarity matrices |

### C. Drug-Drug Similar Matrices

Table 2 lists the symbols used in defining the Kernelized Sparse Regularized Matrix Factorization (KSRMF). By incorporating a non-linear kernel, the kernel function aids in reducing dimensionality and capturing non-linear relationships. In (5) Transfer crucial information onto a common hidden space with lesser dimensions to express information in greater detail. Regularised matrices factorization is essential for success.

$$R\_nm \approx (XY)\_nm = \Sigma\_(i=1)^k X\_ni\ Y\_im \quad (5)$$

The rank (k) for matrices reconstruction is chosen so that (n+m)k nm. The key idea of the suggested remedy reaction predicted is the use of drug-drug or tissue-tissue similarities knowledge to increase the reliability of predictions. The original medication reaction feature area (R) is changed into an experiment universe (K) utilising the Gaussian Curve. By considering drug-drug relationships, the drug-feature attributes are used to describe the fingerprints of each drug. It is assumed that two drugs have similar latent feature vectors (di and d 0 i) if their chemical structures are comparable. Similarly, two cell-line latent feature vectors (ci and c i 0) are considered similar if their fold change (gene expression) is comparable. The primary objective is to minimize dissimilarity between pharmaceuticals and the latent space representing tissues.

## IV. Result and Analysis

### A. GDSC and CCLE Dataset

The proposed approach utilizes the GDSC dataset, which comprises drug response data ( 〖IC〗_50values) for 265 medications and mRNA expression profiles for 1074 cancerous cell lines (as of July 2016). In the case of malignant tissues, the 〖 IC 〗_50 represents the concentration of a drug needed to inhibit 50% of tumor growth. The mRNA expression data provides information about the level of gene involvement in a specific disease domain. Additionally, Isomeric SMILES strings are obtained from the PubChem drug repository to characterize the chemical structure of each compound. Only medications having a SMILES ASCII representation and an IC50 level can be included in the suggested technique. The experimentally determined raw drug response amounts (IC50) are log-normalized and adjusted to a spectrum [-1, 1]. Cell lines with no response frequency are allocated zero. Durable cell types possess a reaction rating that is higher than 0, whilst hypersensitive cell lines possess an outcome measurement that exceeds rather than 0. A final responsive matrices made up of 210 medications and 978 cell populations is created after the initial examination and standardisation of the drug-cell line information in the GDSC collection.

Similarly, the CCLE dataset (as of February 2015) is obtained from an online source (https://portals.broadinstitute.org/cle/data). TABLE II Response amounts for 24 medicines across 504 cell lines make up this dataset. The drug responsiveness value is expressed as a function of the AUCs of the medication responsiveness curve in the CCLE dataset. A greater percentage of the AUC suggests a more potent pharmacological reaction or a higher degree of responsiveness. The SMILES ASCII text and the AUC number have both been taken into consideration while building the final response matrix, much as the GDSC dataset. Thus, the response database includes 23 medicines and 490 cell strains.

TABLE II. THE RATIO OF VICTORIES WHEN A PARTICULAR ALGORITHM IS IMMEDIATELY ASSESSED AGAINST AN ADDITIONAL METHOD TO VICTORIES THAT ARE STATISTICALLY IMPORTANT. FIRST GDSC AND THEN CCLE

| Methods | KBMFs | DLNs | RFs | KSRMFs |
|---|---|---|---|---|
| KBMFs | - | 15/52 | 14/84 | 3/34 |
| DLNs | 25/85 | - | 16/79 | 4/8 |
| RFs | 23/82 | 20/60 | - | 2/28 |
| KSRMFs | 58/111 | 36/106 | 42/116 | - |
| KBMFs | - | 11/25 | 9/18 | 1/6 |
| DLNs | 2/5 | - | 1/7 | 0/3 |
| RFs | 3/9 | 5/21 | - | 0/6 |
| KSRMFs | 4/21 | 12/22 | 7/28 | - |

TABLE III. OUTCOMES OF PAIRWISE FORECASTING USING THE GDSC DATABASE

| Celllines | Drugs | PredictedI $C_{50}(\mu M)$ | CVstd.error |
|---|---|---|---|
| EMC-BAC-2 | Navelbine | -6.5960 | 0.528 err |
| VMCUB-1 | Vepesid | -6.767 | 0.486err |
| MOLM-16 | Rydapt | -5.92 | 0.608err |
| RCH-ACV | Ponatinib | -5.98 | 0.267 err |
| HEYA8 | Selumetinib | -5.76 | 0.384 err |
| MALME3M | AZD6244 | -5.24 | 0.312 err |
| NCIH2122 | Tasigna | -5.13 | 0.729 err |
| FUOV1 | Tk1258 | -4.88 | 0.628 err |
| MALME3M | Vemurafenib | -4.687 | 0.266 err |
| P3HR1 | L685458 | -4.20 | 0.719 err |

The TABLE III MSEs is used to assess how successful the suggested strategy is. Equations 6.18 is used to calculate the MSE, where Nd stands for the sample count, y_d stands for the anticipated chemical reaction vector format and y_d stands for the true drug reaction matrix (target). The tests are run 200 times, and the findings are averaged after each run. According to section 6.3.2, three cutting-edge methodologies are used to compare the outcomes of the KSRMF methodology, and the GDSC and CCLE databases are both freely accessible. The effectiveness of various approaches is evaluated using the average MSE of the medication as an comparison parameter. TABLE IV compares average programme outcomes. The two parameters, 1 and 2, must be tuned throughout the optimisation procedure with KSRMF. On many different datasets, KSRMF is applied repeatedly in order to determine the ideal regularisation values for the parameters (1, 2). Additionally, it displays how the MSE changes when the scores of 1 and 2 change. These variables, in turn, stand for the relative weight of medication and cell-line similarity features. (6) Because both 1 and 2 are equally important to the situation at hand, they should be designated with a comparable value.

TABLE IV. PERFORMANCE OVER TWO DATASETS

| KBMFs | DLNs | RFs | KSRMFs |
|---|---|---|---|
| GDSCs3.45±0.3 | 3.410±0.75 | 3.378±0.10 | 3.28±0.45 |
| CCLEs 0.517±0.9 | 0.518±0.30 | 0.5566±0.42 | 0.5490±0.80 |

$$MSE(d) = 1/N\_d\ (y\_d\hat{}\hat{}-y\_d)\ T\ (y\_d\hat{}\hat{}-y\_d) \qquad (6)$$

To gain a deeper understanding of the effectiveness of each algorithm on a per-drug basis, we conducted paired t-tests to determine the number of statistically significant wins. Table 4 presents a comparison of algorithm performance based on these statistical wins. The results in Table 4 demonstrate that KSRMF outperforms other algorithms for the majority of drugs when compared directly. A negative bar indicates KSRMF's superior performance, while a positive bar represents another algorithm. In most cases, KSRMF exhibits the lowest prediction error and outperforms other prediction algorithms. Notably, KSRMF shows significant improvement in a number of GDSC compounds, including AZD-2281, Nultin-3a, and AZ628.

Additionally, the efficacy of each algorithm on a per-drug basis is evaluated using the paired t-test to determine statistically significant victories. Table 4 displays the results of many approach contrasts, with each row comparing the percentage of statistically important wins for one method versus another. If an algorithm's average square error a particular medication, t, is lower compared to any of the competing methods, it is said to be better. Table 4 highlights that KSRMF outperforms other algorithms for the majority of medications. Visualizations of per-drug immediate comparisons show a disparity in mean square error (MSE) among KSRMF and rival techniques. A negative bar denotes KSRMF's higher performance, whereas an upward bar indicates the efficacy of another algorithms. KSRMF often has the lowest errors in forecasting and works better compared to other forecasting systems. Notably, KSRMF significantly improves the performance of AZD-2281s, Nultin-3as, and AZ628s among other GDSC molecules.

Vinorelbine is a cytotoxicity drug often used for treating different cancers. The first finding from Table 4 on the pair (EMC-BAC-2, Vinorelbine) implies that the non-small cancerous lung cell line EMC-BAC-2 shows vinorelbine susceptibility. This finding aligns with the in-vivo study, which also indicates an improved response rate when vinorelbine and cisplatin are administered together. Another pair examined from the table, NCIH2122 and Nilotinib, has a large cross-validation error, demonstrating that Nilotinib is ineffective against NCIH2122, a lung cancer cell line. Nilotinib is a Bcr-Abl kinases antagonist utilized to treat Parkinson's and Alzheimer's diseases [192]. Despite not taking changes in genes into account, KSRMF accurately predicts drug reactions for experimental cell lines. This approach divides the dataset into 10 equal segments, one of which is utilized to evaluate and the other 9 to serve as training throughout each iteration. For validation, the CCLE dataset uses activity region as a drug response metric with a density (k) of 10. Table 3 displays the averaged outcomes derived from the cross-validation procedure of tenfold for forecasting as was previously discussed.

## V. CONCLUSION

Given the intricacy of the illness and the disparate responses to targeted therapy across individuals with a comparable malignancy type, the result of the research underlines the requirement for novel medications and individualized treatment choices in cancer. But there are considerable difficulties in treating cancer because of how expensive and time-consuming research investigations are.The researchers suggest a cutting-edge strategy named "Kernelled Drug Forecasting Utilizing the Similarity Matrix" to deal with this problem. With the use of this technique, tailored therapies may be efficiently predicted in terms of medication reactions. Every iteration, one portion is tested and the other nine are trained. The CCLE a database, that employs activation surface as the drug response variables, undergoes to the validation procedure with dimensionality (k) fixed at 10. By using this strategy, the research aims to provide a more effective and precise method of anticipating medication reactions and promoting individualized cancer

therapy.By combining different types of omics data, like genomes, transcriptomics, it is and proteomics, for example we might be able to learn more about the way drugs work at the molecular level. By using this multi-omics information it may be possible to increase the precision of medication response forecasting and create more individualized treatment strategies.

## REFERENCES


[1] Barretina,J.,Caponigro,G.,Stransky,N.,Venkatesan, K.,Margolin,A.A., Kim, S., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (7391), 603–607. doi:10.1038/nature11003

[2] Deng, L., Cai, Y., Zhang, W., Yang, W., Gao, B., and Liu, H. (2020). Pathway-guided deep neural network toward interpretable and predictive modeling of drug sensitivity. J. Chem. Inf. Model. 60 (10), 4497–4505. doi:10.1021/acs.jcim.0c00331

[3] Feng, J., Zhang, H., and Li, F. (2020). Investigate the relevance of major signaling pathways in cancer survival using a biologically meaningful deep learning model. Biorxiv.

[4] Garnett,M. J., Edelman, E. J.,Heidorn, S. J., Greenman,C.D., Dastur,A., Lau, K.W., et al. (2012). Systematic identification of genomicmarkers of drug sensitivity in cancer cells. Nature 483 (7391), 570–575. doi:10.1038/nature11005

[5] Goldman,M., Craft, B.,Brooks,A. N., and JingchunZhu, D.H. (2018).TheUCSCXena Platform for cancer genomics data visualization and interpretation. Biorxiv.

[6] Hao, J., Kim, Y., Kim, T.-K., and Kang, M. (2018). PASNet: pathway-associated sparse deep neural network for prognosis prediction from high-throughput data. BMC Bioinformatics 19 (1), 1–13. doi:10.1186/s12859-018-2500-z

[7] Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., et al. (2017). The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. Cancer Res. 77 (13), 3564–3576. doi:10. 1158/0008-5472.CAN-17-0489

[8] Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. doi:10.1093/nar/28.1.27 Kong, J., Lee, H., Kim, D., Han, S. K., Ha, D., Shin, K., et al. (2020). Network-based machine learning in colorectal and bladder organoidmodels predicts anti-cancer drug efficacy in patients. Nat. Commun. 11 (1), 1–13. doi:10.1038/s41467-020-19313-8

[9] Kuenzi, B. M., Park, J., Fong, S. H., Sanchez, K. S., Lee, J., Kreisberg, J. F., et al. (2020). Predicting drug response and synergy using a deep learning model of human cancer cells. Cancer Cell 38 (5), 672–684. doi:10.1016/j.ccell.2020.09.014

[10] Li, M., Wang, Y., Zheng, R., Shi, X., li, y., Wu, F., et al. (2019). DeepDSC: a deep learning method to predict drug sensitivity of cancer cell lines. Ieee/acm Trans. Comput. Biol. Bioinf. [Epub ahead of print]. doi:10.1109/TCBB.2019.2919581

[11] Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., and Kanehisa, M. (1999). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 27, 29. doi:10.1093/nar/27.1.29

[12] Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., and Klambauer, G. (2018). DeepSynergy: predicting anti-cancer drug synergy with deep learning. Bioinformatics 34, 1538. doi:10.1093/bioinformatics/btx806

[13] Sakellaropoulos, T., Vougas, K., Narang, S., Koinis, F., Kotsinas, A., Polyzos, A., et al. (2019). A deep learning framework for predicting response to therapy in cancer. Cell. Rep. 29 (11), 3367–3373. doi:10.1016/j.celrep.2019.11.017

[14] Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., et al. (2018). Oncogenic signaling pathways in the cancer genome atlas. Cell 173 (2), 321–e10. doi:10.1016/j.cell.2018.03.035

[15] Sheng, J., Li, F., and Wong, S. T. C. (2015). Optimal drug prediction from personal genomics profiles. IEEE J. Biomed. Health Inform. 19 (4), 1264–1270. doi:10. 1109/JBHI.2015.2412522

[16] Suphavilai, C., Bertrand, D., and Nagarajan, N. (2018). Predicting cancer drug response using a recommender system. Bioinformatics 34 (22), 3907–3914. doi:10.1093/bioinformatics/bty452

[17] Wang, S.,Huang, E., Cairns, J., Peng, J., Wang, L., and Sinha, S. (2019). Identification of pathways associated with chemosensitivity through network embedding. PLOS Comput. Biol. 15 (3), e1006864. doi:10.1371/journal.pcbi.1006864

[18] Wang, Y., Fang, J., and Chen, S. (2016). Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic properties. Sci. Rep. 6 (1), 32679. doi:10.1038/srep32679

[19] Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., et al. (2013). Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41 (D1), D955–D961. doi:10.1093/nar/gks1111

[20] Yu, M. K., Ma, J., Fisher, J., Kreisberg, J. F., Raphael, B. J., and Ideker, T. (2018). Visible machine learning for biomedicine. Cell 173 (7), 1562–1565. doi:10.1016/j.cell.2018.05.056

[21] Zhang, H., Feng, J., Zeng, A., Payne, P., and Li, F. (2020). Predicting tumor cell response to synergistic drug combinations using a novel simplified deep learning model. AMIA 2020 Annu. Symp. [Epub ahead of print]. doi:10.1101/2020.04.10.036491

[22] Zhang, N.,Wang, H., Fang, Y.,Wang, J., Zheng, X., and Liu, X. S. (2015). Predicting anticancer drug responses using a dual-layer integrated cell line-drug network model. Plos Comput. Biol. 11 (9), e1004498. doi:10.1371/journal.pcbi.1004498

[23] Zhang, T., Zhang, L., Payne, P., and Li, F. (2018). Synergistic drug combination prediction by integrating multi-omics data in deep learning models. arXiv181107054.

[24] Preethi, P., & Asokan, R. (2019). A high secure medical image storing and sharing in cloud environment using hex code cryptography method—secure genius. Journal of Medical Imaging and Health Informatics, 9(7), 1337-1345.

[25] Kulurkar, P., kumar Dixit, C., Bharathi, V. C., Monikavishnuvarthini, A., Dhakne, A., & Preethi, P. (2023). AI based elderly fall prediction system using wearable sensors: A smart home-care technology with IOT. Measurement: Sensors, 25, 100614.